The latest UDMI aims to align classifications with pathology and clinical practice, bringing numerous changes to the 2018 ...

Asymptomatic patients will now be covered and more flexibility has been given to heart teams for individualizing patient care ...

The data “give you pause” when considering closure, especially for women who can tolerate DOACs, Christine Albert says.

SHASTA-3/4 trial data show plozasiran, like olezarsen, can drastically lower triglycerides and the risk of acute pancreatitis ...

It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

Multiple US health systems have been awaiting the authorization before taking the Queen of Hearts platform live.

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

Mirvat Alasnag talks with host Yael L. Maxwell about the need to prove herself, social media, and partnerships with patients.

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.